In a prospective study, researchers analyzed the association between insulin-related dietary indices and risk for incident gout among US women older than 30 years.
Patients with COVID-19 who had the highest quartile of serum uric acid at hospital admission had increased odds of acute kidney injury.
New analysis suggests that gout prevalence is 21% among patients on peritoneal dialysis and 13% among those on hemodialysis.
New findings complement previous research showing no renoprotective effect of urate-lowering therapy in patients with chronic kidney disease.
In a study of kidney transplant recipients treated with pegloticase for uncontrolled gout, the proportion of patients experiencing gout flares declined over the treatment period.
Some 15% of patients receiving dialysis in the United States have a gout diagnosis, according to a recent study.
ALLN-346 is an investigational, first-in-class, nonabsorbed, orally-administered enzyme that breaks down urate in the gastrointestinal tract.
The double-blind, placebo-controlled MIRROR trial included 152 adults with uncontrolled gout.
Researchers compared cardiovascular risk among patients with gout who received treatment with allopurinol vs benzbromarone.
Researchers of a metagenomic analysis assessed the taxonomic and functional signatures of the gut microbiome in gout and its association with clinical parameters and response to therapeutic interventions.